Getting together to build the future of in vitro models

On March 12, we gathered several international experts on organ-on-chip technology and kidney diseases in Maastricht to discuss how to bring advanced in vitro research technologies from bench to business. The workshop covered a diverse set of topics ranging from the importance of international standards for organ-on-chip and ethical considerations regarding organoid technologies to insightful perspectives on pharmaceutical development targeting kidney fibrosis and BK virus infection.

Take the opportunity to check out the recorded workshop with talks from Carlos Mota, Andies D. van der Meer, and Maxcence Gaillard and a roundtable discussion also including Eric van der Veer and Jitske Jansen. Se below for detail information about the speakers.

Speakers

ANDRIES D. VAN DER MEER
Professor of Microphysiological Systems. Department of Bioengineering Technologies. Research Universirty of Twente

Prof. Dr. Andries van der Meer is Full Professor of Microphysiological Systems at the University of Twente, The Netherlands. Van der Meer is the president of the European Organ-on-Chip Society (EUROoCS). He also served as chair of the Focus Group on Standardization for Organ-on-Chip of the European standardization body CEN CENELEC. He is a leading international proponent of standards-driven innovation in the field of organs-on-chips.

Before joining the University of Twente in 2015, Dr. Van der Meer worked as a Senior Research Fellow at Harvard Medical School and the Wyss Institute of Harvard University, Cambridge, MA, USA. He has a Ph.D. in Biomedical Engineering (University of Twente, 2010), and a M.Sc. in Biology (University of Groningen, 2005).

Read more at the Research University of Twente website.

CARLOS MOTA
Assistant Professor Department of Complex Tissue Regeneration
Maastricht University / BIRDIE

Dr. Carlos Mota is an Assistant Professor in the Department of Complex Tissue Regeneration, MERLN Institute for Technology-inspired Regenerative Medicine, Maastricht University. Dr. Mota received his PhD in Biomaterials from the BIOS research doctorate school in Biomolecular Sciences at the University of Pisa, Italy, in March 2012. His doctoral studies were focused on the development of new approaches for the fabrication of polymeric scaffolds for Tissue Engineering applications. Currently, his main research interests are focused on bioprinting and additive manufacturing techniques for the development of tissue engineered constructs and in vitro models.

Read more at the MERLN Institue website.

ERIC VAN DER VEER
Founder and Chief Innovation Officer
Hybridize Therapeutics

Eric van der Veer PhD studied chemistry at the University of Amsterdam and obtained his PhD degree at the University of Western Ontario (London, Ontario, Canada), where he alongside high-impact publications, obtained several patents in the field of cellular aging. He returned to the Netherlands and started his own research group at the Leiden University Medical Center (Nephrology) specializing in RNA biology. In 2015, Eric transitioned his research focus to the development of RNA therapeutic strategies for kidney diseases, thereby focusing on BK virus in the setting of kidney and hematopoietic stem cell transplantation. In 2019, Eric founded Hybridize Therapeutics with the goal to move these RNA-based technologies to kidney patients. In 2022, Hybridize Therapeutics outlicensed this BK virus-targeting ASO to AiCuris Anti-Infectives Cures AG.

Read more at the Hybridize Therapeutics website.

JITSKE JANSEN
Group Leader Target Validation
Sequantrix

Dr. Jitske Jansen is the Group Leader Target Validation at Sequantrix^TM. She is the awardee of the TOPX Female2Follow Rising Star in Science Award 2022. Jitske has been instrumental in developing complex organoid model systems and has been a Group Leader for Translational Kidney Research at the Institute of Experimental Medicine and Systems Biology at Uniklinik RWTH Aachen. Previously, she was Assistant Professor at Radboud University and Post-Doc at Utrecht University and the Murdoch Childrens Research Institute (Australia) and was awarded several prestigious personal grants during the past years. Jitske received her Ph.D. in Biomedical Sciences from the Radboud University Medical Center, Netherlands and she received the Young Investigator Award from the Federation of European Pharmacological Societies for her Ph.D. research.

Speakers

Related